Complementary role of 18F-fluorodeoxyglucose positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer

Journal of the Formosan Medical Association

Volumn 101, Issue 7, 2002, Pages 459-467

  Hsu, Chung Huei ^a   Liu, Ren Shyan ^a   Wu, Chih Hsiung ^a   Chen, Su Mei ^a   Shih, Li Sun ^a  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

131I; 201T1; Dedifferentiation; FDG PET; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; MEDRONATE TECHNETIUM TC 99M; THALLIUM; THYROGLOBULIN; THYROTROPIN; THYROXINE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER INVASION; CANCER RADIOTHERAPY; CERVICAL LYMPH NODE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIET THERAPY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LUNG METASTASIS; LUNG NODULE; LYMPH NODE METASTASIS; MALE; MEDIASTINUM METASTASIS; PELVIS INJURY; THYROID CANCER; THYROIDECTOMY; TUMOR DIFFERENTIATION; WHOLE BODY SCINTISCANNING; BLOOD; MIDDLE AGED; SCINTISCANNING; THYROID TUMOR;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036629529     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Schlumberger MJ: Papillary and follicular thyroid cancer. N Engl J Med 1998;338:297-306.
2. Wong CYO, Dworkin HJ: Role of FDG PET in metastatic thyroid cancer. J Nucl Med 1999;40:993-4.
3. Reynolds JC, Robbins J: The changing role of radioiodine in the management of differentiated thyroid cancer. Semin Nucl Med 1997;27:152-64.
4. Haugen BR, Lin EC: Isotope imaging for metastatic thyroid cancer. Endocrinol Metab Clin North Am 2001;30:469-92.
5. Dietlein M, Scheidhauer K, Voth E, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24:1342-8.
6. Grunwald F, Kalicke T, Feine U, et al: Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: result of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
7. Feine U: Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer. Eur J Endocrinol 1998;138:492-6.
8. Feine U, Lietzenmayer R, Hanke JP, et al: Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.
9. 131I whole-body scan. J Nucl Med 1999;40:986-92.
10. 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84:2291-302.
11. 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:3779-86.
12. 18F fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001;234:804-11.
13. 131I scanning results after therapy. J Nucl Med 2001;42:1464-9.
14. Moog F, Linke R, Manthey N, et al: Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000;41:1989-95.
15. Grunwald F, Menzel C, Bender H, et al: Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998;39:1903-6.
16. Bares R, Lietzenmayer R, Feine U: The role of PET for detection and treatment control of thyroid cancer. Thyroid 1998;8:1220. [Abstract]
17. Lawson MA, Seabold JE, Duick DS, et al: Uptake of FDG correlates with tumor aggressiveness in high risk patients with differentiated thyroid cancer (DTC) and its variants. Thyroid 1998;8:1221. [Abstract]
18. 18F-fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107-13.
19. Simon D, Koehrle J, Reiners C, et al: Redifferentiation therapy in thyroid cancer-results of a multicenter pilot study. Thyroid 1998;8:1217. [Abstract]
20. Sakamoto A, Kasai N, Sugano H: Poorly differentiated carcinoma of the thyroid, a clinicopathologic entity for a high-risk group of papillary and follicular carcinoma. Cancer 1983;52:1849-55.
21. Hoie J, Stenwig AE, Kullmann G, et al: Distant metastases in papillary thyroid cancer, a review of 91 patients. Cancer 1988;61:1-6.
22. Schlumberger M, Challeton C, Vathaire FD, et al: Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996;37:598-605.
23. Vassilopoulou-Sellin R, Klein MJ, Smith TH, et al: Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer 1993;71:1348-52.
24. Piekarski D-J, Schlumberger M, Leclere J, et al: Chest computed tomography (CT) in patients with micronodular lung metastases of differentiated thyroid carcinoma. Int J Radiat Oncol Biol Phys 1985;11:1023-7.
25. Sisson J, Jamadar DA, Kazerooni EA, et al: Treatment of micronodular lung metastases of papillary thyroid cancer: are the tumors too small for effective irradiation from radioiodine? Thyroid 1998;8:215-21.
26. Tenenbaum F, Schlumberger M, Bonnin F, et al: Usefulness of technetium-99m hydroxymethylene diphosphonate scans in localizing bone metastases of differentiated thyroid carcinoma. Eur J Nucl Med 1993;20:1168-74.
27. Marcocci C, Pacini F, Elisei R, et al: Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. Surgery 1989;106:960-6.
28. Lorberboym M, Murthy S, Mechanick JI, et al: Thallium-201 and iodine-131 scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1996;37:1487-91.
29. Oyen WJG, Verhagen C, Saris E, et al: Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal. J Nucl Med 2000;14:643-6.
30. 201T1 in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 2001;42:414-9.